维普中文期刊产品整合服务

Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma:a multi-center propensity score matched analysis of real-world practice

查看全文 作　　者：Shaohua [1,2]Li;Jie [1,2]Mei;Qiaoxuan [2,3]Wang;Feng [4]Shi;Hongyan [5]Liu;Ming [2,6]Zhao;Lianghe [1,2]Lu;Yihong [2,7]Ling;Zhixing [2,8]Guo;Yabing [5]Guo;Xiaoming [4]Chen;Ming [1,2]Shi;Wan Yee [9]Lau;Wei [1,2]Wei;Rongping [1,2]Guo 高影响力作者 机构地区：[1]Department of Liver Surgery,Sun Yat-sen University Cancer Center,Guangzhou,China;[2]State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Guangzhou,China;[3]Department of Radiation Oncology,Sun Yat-sen University Cancer Center,Guangzhou,China;[4]Department of Interventional Radiology,Guangdong Provincial People’s Hospital,Guangdong Academy of Medical Sciences,Guangzhou,China;[5]State Key Laboratory of Organ Failure Research,Guangdong Provincial Key Laboratory of Viral Hepatitis Research,Department of Infectious Diseases,Nanfang Hospital,Southern Medical University,Guangzhou,China;[6]Department of Interventional Radiology,Sun Yat-sen University Cancer Center,Guangzhou,China;[7]Department of Pathology,Sun Yat-sen University Cancer Center,Guangzhou,China;[8]Department of Ultrasound,Sun Yat-sen University Cancer Center,Guangzhou,China;[9]Faculty of Medicine,the Chinese University of Hong Kong,Shatin,New Territories,Hong Kong,China高影响力机构 出　　处：《Hepatobiliary Surgery and Nutrition》索引2021年第10卷第5期,共23页高影响力期刊 基　　金：This study was supported by the National Natural Science Foundation of China(No.81871985);Natural Science Foundation of Guangdong Province(No.2018A0303130098 and No.2017A030310203);Science and Technology Planning Project of Guangdong Province(No.2017A020215112);Medical Scientific Research Foundation of Guangdong Province(No.A2017477);Science and Technology Planning Project of Guangzhou(No.201903010017 and No.201904010479);Clinical Trials Project(5010 Project)of Sun Yat-sen University(No.5010-2017009);and Clinical Trials Project(308 Project)of Sun Yat-sen University Cancer Center(No.308-2015-014). 摘　　要：Background:To compare the treatment effectiveness and safety among transarterial infusion chemotherapy(TAI)with FOLFOX regimen,transarterial chemoembolization(TACE),and sorafenib in patients with BCLC stage C hepatocellular carcinoma(HCC).Methods:The data of consecutive patients with BCLC stage C HCC treated with TAI,TACE,or sorafenib from January 2015 to December 2018 at three centers were retrospectively analyzed.Propensity-score matched(PSM)analysis was pairwise performed to reduce selection bias.Treatment effectiveness and safety were evaluated and compared using the Kaplan-Meier method,log-rank test,Cox regression models,andχ2 test.Results:The median overall survival(OS)in the matched TAI cohort was significantly longer than the sorafenib cohort(19.6 vs.7.5 months,P=0.009),and the TACE cohort(estimated 27.8 vs.6.6 months,P<0.001).The difference in median progression-free survival(PFS)between the matched TAI and sorafenib cohorts was not significant(5.8 vs.2.3 months,P=0.219).The median PFS in the matched TAI cohort was significantly longer than the TACE cohort(6.5 vs.2.8 months,P<0.001).The objective response rate(ORR)in the matched TAI cohort was significantly higher than the sorafenib cohort(36.4%vs.0.0%,P<0.001)and the TACE cohort(48.7%vs.4.7%,P<0.001).The incidences of adverse events(AEs)were similar among these three cohorts.Conclusions:TAI with FOLFOX regimen was an effective and safe therapy that improved survival of patients with BCLC stage C HCC. 关 键 词：Hepatocellular carcinoma(HCC) transarterial infusion chemotherapy SORAFENIB transarterial chemoembolization FOLFOX
相关文献

参考文献(38)

引证文献(3)

耦合文献(225)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费